Metastatic Male Breast Cancer: A Retrospective Cohort Analysis
Metastatic Male Breast Cancer: A Retrospective Cohort Analysis
复制标题
DOI：
10.1159/000365953
复制
发表时间：
2014-01-01
期刊：
影响因子：
2.1
通讯作者：
Rudlowski, Christian
中科院分区：
文献类型：
--
作者：
Foerster, Robert;Schroeder, Lars;Rudlowski, Christian
背景：转移性男性乳腺癌（MMBC）是一种罕见疾病。鉴于其发病率低，有关肿瘤生物学，目前的治疗方案和生存率的数据是稀缺的。患者和方法：对1995年至2011年期间在德国地区癌症登记中心连续登记的MMBC患者进行了病历审查。记录肿瘤特征、治疗和生存率并进行统计学评价。结果：男性41例，占MBC患者总数的25.6%。16例（39%）患者出现原发转移，25例（61%）患者出现复发转移。发生转移后的中位生存期为32个月。中位总生存期（OS）为68个月。68.3%（n = 28）的队列接受了支持内分泌治疗的全身治疗（n = 25，61.9%）。在接受全身治疗的患者中观察到转移性OS延长（p = 0.02）。接受内分泌治疗的转移患者的生存率显着延长。此外，接受姑息性化疗的患者与未接受化疗的患者相比有显著的生存获益。结论：我们的研究结果表明，姑息性化疗和内分泌治疗的形式的系统治疗改善了MMBC的结果。因此，MMBC的治疗应基于女性乳腺癌的指南，这似乎是合理的。
Background: Metastasized male breast cancer (MMBC) is a rare disease. Given its low incidence, data regarding tumor biology, current treatment options, and survival rates are scarce. Patients and Methods: A chart review was performed of MMBC patients consecutively registered in regional cancer registries in Germany between 1995 and 2011. Tumor characteristics, treatment, and survival rates were documented and statistically evaluated. Results: 41 men with MMBC represented 25.6% of a total of 160 patients with MBC. 16 (39%) patients showed primary metastases, and 25 (61%) had recurrent metastases. Median survival from occurrence of metastasis was 32 months. Median overall survival (OS) was 68 months. 68.3% (n = 28) of the cohort received systemic therapy favoring endocrine therapy (n = 25, 61.9%). Prolonged metastatic OS (p = 0.02) was observed in patients having had a systemic treatment. Metastatic patients having received endocrine treatment showed significantly prolonged survival rates. Furthermore, patients receiving palliative chemotherapy had a significant survival benefit compared to those in whom chemotherapy was omitted. Conclusion: Our results suggest that systemic treatment in the form of both palliative chemotherapy and endocrine therapy improves outcome of MMBC. Therefore, it seems reasonable that treatment of MMBC should be based on the guidelines for female breast cancer.